Somewhat Positive Media Coverage Somewhat Unlikely to Affect MetLife (MET) Share Price

Headlines about MetLife (NYSE:MET) have trended somewhat positive recently, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. MetLife earned a coverage optimism score of 0.06 on Accern’s scale. Accern also assigned news stories about the financial services provider an impact score of 46.304476078021 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

These are some of the news stories that may have impacted Accern’s scoring:

NYSE:MET traded up $0.05 during mid-day trading on Friday, reaching $47.49. The stock had a trading volume of 4,377,761 shares, compared to its average volume of 5,506,473. The stock has a market capitalization of $49,230.18, a price-to-earnings ratio of 10.55, a price-to-earnings-growth ratio of 0.84 and a beta of 1.24. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.15 and a quick ratio of 0.15. MetLife has a 12 month low of $43.38 and a 12 month high of $55.91.

MetLife (NYSE:MET) last announced its quarterly earnings data on Tuesday, February 13th. The financial services provider reported $0.64 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.41). The firm had revenue of $15.79 billion during the quarter, compared to the consensus estimate of $15.89 billion. MetLife had a net margin of 5.69% and a return on equity of 8.59%. During the same period last year, the business earned $1.28 earnings per share. analysts anticipate that MetLife will post 4.91 EPS for the current fiscal year.

Several brokerages have recently commented on MET. UBS reaffirmed a “neutral” rating and set a $51.00 target price (down from $52.00) on shares of MetLife in a report on Friday, March 2nd. Wells Fargo set a $60.00 target price on shares of MetLife and gave the stock a “buy” rating in a report on Tuesday, February 13th. Sandler O’Neill set a $47.00 target price on shares of MetLife and gave the stock a “hold” rating in a report on Thursday, April 5th. Goldman Sachs reaffirmed a “buy” rating on shares of MetLife in a report on Wednesday, January 31st. Finally, Morgan Stanley lowered their target price on shares of MetLife from $59.00 to $58.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 14th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $56.75.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect MetLife (MET) Share Price” was first posted by Stock Observer and is owned by of Stock Observer. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at

About MetLife

MetLife, Inc engages in the insurance, annuities, employee benefits, and asset management businesses. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and stable value products, including general and separate account guaranteed interest contracts, and private floating rate funding agreements.

Insider Buying and Selling by Quarter for MetLife (NYSE:MET)

Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with's FREE daily email newsletter.

Leave a Reply